Anlon Healthcare plans ₹130 cr Rajkot build to back FY28 revenue target
The micro-cap is adding organic capacity after two acquisitions. A half-debt funding plan and early-stage M&A talks frame the next leg of growth.
— 1 earlier story on Anlon Healthcare Ltd. →What's new
- Anlon plans a ₹130 crore organic expansion at Rajkot, targeting commercial production by Q1 FY28.
- The build is funded by a ₹65-70 crore bank term loan and internal accruals.
- Management is in early-stage talks for acquisitions in finished dosage and peptide manufacturing.
Why this matters
The Rajkot capex is the first concrete step beyond the acquired portfolio of Apiqo Organics and Bizotic Life Science. For a company guiding for near-doubling revenue from FY27 to FY28, this build signals a bet on organic demand the current order book alone doesn't fully cover.
What we're watching
- Finalisation of the ₹65-70 crore term loan and the resulting debt load.
- Conversion of early-stage acquisition talks into concrete deals.
- Execution against the ₹280-300 crore order book that anchors FY27 guidance.
The full read
Anlon Healthcare is planning a ₹130 crore organic build at Rajkot. That's new. Until now, growth came from buying Apiqo Organics and Bizotic Life Science. The new plant targets commercial production by Q1 FY28. Funding is half debt, via a ₹65-70 crore term loan, and half internal cash. Management reiterated revenue guidance of ₹380-400 crore for FY27 and ₹700-800 crore for FY28. The current order book of ₹280-300 crore covers a large chunk of the near-term target. The longer-term target requires more. So management is also talking to potential acquisition targets in finished dosage and peptide manufacturing. The talk is early-stage. The capex and the acquisition pipeline together map a path to the growth curve guidance implies. The financing mix is the first real constraint to watch.
Questions answered
- How is Anlon funding the Rajkot plant?
- The ₹130 crore expansion will be funded by a ₹65-70 crore bank term loan and the rest from internal accruals. Management did not disclose the exact debt-equity split.
- When will the new capacity come online?
- Commercial production from the Rajkot facility is targeted for the first quarter of FY28, or April-June 2027.
- What does the order book cover relative to FY27 guidance?
- The ₹280-300 crore order book represents roughly 75-80% of the midpoint of the ₹380-400 crore revenue target for FY27.
- What kind of acquisitions is management exploring?
- Management is in early-stage discussions for targets in finished dosage forms and peptide manufacturing, following the consolidation of Apiqo Organics and Bizotic Life Science.
Story so far
All notes on AHCL →- 9 Jun 2026 · 11:24 AM IST Anlon Healthcare plans ₹130 cr Rajkot build to back FY28 revenue target
- 6d ago Anlon's Rajkot capex balloons to ₹130 cr; ₹28 cr distributor default disclosed